Patents by Inventor Tanja Fauti
Tanja Fauti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11952421Abstract: The present invention relates to bispecific antibodies against ROR1 and CD3, their manufacture and use.Type: GrantFiled: October 8, 2015Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Publication number: 20240043535Abstract: The present invention generally relates to novel immune activating Fc domain binding molecules for activation of immune cells and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: December 16, 2022Publication date: February 8, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Maria Amann, Alejandro Carpy Gutierrez Cirlos, Christina Claus, Laura Codarri Deak, Diana Darowski, Tanja Fauti, Claudia Ferrara Koller, Anne Freimoser-Grundschober, Sylvia Herter, Thomas Hofer, Christian Klein, Laura Lauener, Stephane Leclair, Ekkehard Moessner, Christiane Neumann, Pablo Umaña, Ali Bransi, Marlena Surówka
-
Publication number: 20230416365Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.Type: ApplicationFiled: November 17, 2022Publication date: December 28, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
-
Publication number: 20230355754Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.Type: ApplicationFiled: March 6, 2023Publication date: November 9, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
-
Publication number: 20230340160Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: April 17, 2023Publication date: October 26, 2023Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane NEUMANN, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA
-
Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
Patent number: 11639397Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: May 5, 2014Date of Patent: May 2, 2023Assignee: Roche Glycart AGInventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umana -
Patent number: 11608376Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.Type: GrantFiled: December 19, 2019Date of Patent: March 21, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Guy Georges, Thomas Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Johannes Sam, Pablo Umaña, Jenny Thom, Stephan Gasser, Jean-Baptiste Vallier, Tanja Fauti
-
Publication number: 20220259318Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: January 28, 2022Publication date: August 18, 2022Applicant: Hoffmann-La Roche Inc.Inventors: ALEXANDER BUJOTZEK, TONY CHRISTOPEIT, TANJA FAUTI, GEORG FERTIG, HÉLÈNE CÉCILE HAEGEL, CHRISTIAN KLEIN, THOMAS KRAFT, STEFAN LORENZ, MAUD LÉA MAYOUX, ANNELIESE SCHNEIDER
-
Publication number: 20220098305Abstract: The present invention relates to novel ICOS antibodies and tumor-targeted agonistic ICOS antigen binding molecules comprising them, pharmaceutical compositions comprising these molecules, and methods of using the same.Type: ApplicationFiled: December 15, 2021Publication date: March 31, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Stefan DENGL, Tanja FAUTI, Jens FISCHER, Lucas HABEGGER, Christian KLEIN, Esther KOENIGSBERGER, Jens NIEWOEHNER, Johannes SAM, Pablo UMAÑA, Joerg ZIELONKA
-
Publication number: 20210230278Abstract: The present invention generally relates to antibodies that bind to HLA-A2/MAGE-A4, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: December 17, 2020Publication date: July 29, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Tina Weinzierl, Lydia Jasmin Hanisch, Alexander Bujotzek, Alejandro Carpy Gutierrez Cirlos, Stefan Klostermann, Christian Klein, Simon Patrick Keiser, Tanja Fauti, Estelle Marrer-Berger, Pablo Umaña
-
Publication number: 20210070873Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.Type: ApplicationFiled: November 4, 2020Publication date: March 11, 2021Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
-
Patent number: 10851171Abstract: An antibody specifically binding to human BCMA, characterized in that the binding of said antibody is not reduced by APRIL and not reduced by BAFF, said antibody does not alter APRIL-dependent NF-?B activation, BAFF-dependent NF-?B activation, and does not alter NF-?B activation without BAFF and APRIL is useful as a therapeutic agent.Type: GrantFiled: April 4, 2018Date of Patent: December 1, 2020Assignee: ENGMAB SARLInventors: Minh Diem Vu, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Marina Bacac, Tanja Fauti, Christian Klein, Pablo Umana, Samuel Moser
-
Publication number: 20200347147Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: July 23, 2020Publication date: November 5, 2020Inventors: Marina BACAC, Tanja FAUTI, Sabine IMHOF-JUNG, Christian KLEIN, Stefan KLOSTERMANN, Ekkehard MOESSNER, Michael MOLHOJ, Christiane NEUMANN, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Publication number: 20200306373Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.Type: ApplicationFiled: June 17, 2020Publication date: October 1, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
-
Patent number: 10766967Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: September 30, 2016Date of Patent: September 8, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Marina Bacac, Tanja Fauti, Sabine Imhof-Jung, Christian Klein, Stefan Klostermann, Ekkehard Moessner, Michael Molhoj, Christiane Neumann, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20200255521Abstract: A bispecific antibody specifically binding to the two targets human CD3? (further named also as “CD3”) and the extracellular domain of human ROR1 (further named also as “ROR1”), characterized in that the bispecific antibody does not internalize in a cell based assay at 37° C. during 2 hrs, using ROR1-positive B-CLL cells and used at an antibody concentration of 1 nM, whereby not internalize means, that the mean fluorescence intensity (MFI), as detected by flow cytometry, of a bispecific antibody upon binding to ROR1-positive primary B-CLL cells measured at time 0 is not reduced for more than 50%, preferably not more than 30% when re-measured after a 2 hr-incubation at 37° C. and which is useful for the treatment of B-cell malignancies like Chronic Lymphocytic Leukemia or B-cell disorders expressing ROR1 and ROR1-positive solid tumors.Type: ApplicationFiled: January 27, 2020Publication date: August 13, 2020Inventors: Minh Diem VU, Klaus Strein, Ekkehard Moessner, Ralf Hosse, Oliver Ast, Anne Freimoser-Grundschober, Tanja Fauti, Ramona Murr, Christian Klein, Pablo Umana, Samuel Moser
-
Publication number: 20200199234Abstract: The present invention relates to tumor targeted bispecific agonistic antigen binding molecules characterized by monovalent binding to CD28, methods for their production, pharmaceutical compositions containing these antibodies, and methods of using the same.Type: ApplicationFiled: December 19, 2019Publication date: June 25, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Guy GEORGES, Thomas HOFER, Ralf HOSSE, Christian KLEIN, Ekkehard MOESSNER, Johannes SAM, Pablo UMAÑA, Jenny THOM, Stephan GASSER, Jean-Baptiste VALLIER, Tanja FAUTI
-
Patent number: 10253104Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.Type: GrantFiled: August 3, 2015Date of Patent: April 9, 2019Assignee: ENGMAB AGInventors: Minh Diem Vu, Klaus Strein, Oliver Ast, Marina Bacac, Lydia Jasmin Hanisch, Tanja Fauti, Anne Freimoser-Grundschober, Ralf Hosse, Christian Klein, Ekkehard Moessner, Samuel Moser, Ramona Murr, Pablo Umana, Sabine Jung-Imhof, Stefan Klostermann, Michael Molhoj, Joerg Regula, Wolfgang Schaefer
-
Patent number: 10087250Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: October 3, 2013Date of Patent: October 2, 2018Assignee: Roche Glycart AGInventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umaña
-
Publication number: 20180273643Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: March 12, 2018Publication date: September 27, 2018Inventors: Oliver AST, Peter BRUENKER, Tanja FAUTI, Anne FREIMOSER-GRUNDSCHOBER, Christiane Neumann, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA